Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04288115 · ClinicalTrials.gov registry record · Phase 4
Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism
A Phase 4 study of Subclinical Hypothyroidism, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT04288115: Completed Phase 4 study of Subclinical Hypothyroidism, sponsored by VA Office of Research and Development.
NCT04288115 is a Phase 4 study of Subclinical Hypothyroidism that has completed, run by VA Office of Research and Development. The registered enrollment target is 52 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04288115, a Phase 4 study of Subclinical Hypothyroidism, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose the following hypothesis: discontinuation of levothyroxine (LT4) for veterans with subclinical hypothyroidism (SCH) will be feasible, acceptable, and safe and will not negatively affect their Quality of Life (QoL). The investigators aim to evaluate the feasibility of LT4 discontinuation among veterans with SCH and determine the changes in QoL measures, lipids, and adverse events.
Primary Outcome
Percent of eligible participants approached who consented to participate during the recruitment phase.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Levothyroxine
Study Locations (1)
Arkansas
- Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 4 |
What the finished NCT04288115 record still lists
NCT04288115 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Subclinical Hypothyroidism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04288115 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT04288115 about?
NCT04288115 is a clinical study titled "Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism". The investigators propose the following hypothesis: discontinuation of levothyroxine (LT4) for veterans with subclinical hypothyroidism (SCH) will be feasible, acceptable, and safe and will not negatively affect their Quality of Life (QoL). The investigators aim to evaluate the feasibility of LT4 di...
What is the current status of trial NCT04288115?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2021-03-24. Estimated completion is 2022-12-31.
What conditions does trial NCT04288115 study?
This clinical trial studies the following conditions: Subclinical Hypothyroidism.
What interventions are being tested in trial NCT04288115?
The interventions under investigation include: Placebo (OTHER), Levothyroxine (DRUG).
Who is sponsoring clinical trial NCT04288115?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04288115 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subclinical Hypothyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04288115's enrollment target sits among peer trials
52 1233rd of 2000 higher than 753 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI